NCT04195750 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 374
- group Id
- BG001
- value
- 372
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 755
- units
- Participants
- groups
- description
- Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.
- id
- BG000
- title
- Belzutifan
- description
- Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.
- id
- BG001
- title
- Everolimus
- description
- Non-Randomized participants enrolled into the Safety Run-in received up to 120 mg of belzutifan QD.
- id
- BG002
- title
- Safety Run-In
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.2
- value
- 61.6
- group Id
- BG001
- spread
- 9.7
- value
- 63.1
- group Id
- BG002
- spread
- 6.6
- value
- 70.0
- group Id
- BG003
- spread
- 10.0
- value
- 62.4
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 77
- group Id
- BG001
- value
- 88
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 169
- title
- Female
- measurements
- group Id
- BG000
- value
- 297
- group Id
- BG001
- value
- 284
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 586
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 37
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 78
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 300
- group Id
- BG001
- value
- 303
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 612
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 33
- group Id
- BG001
- value
- 32
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 65
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 5
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 47
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 99
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 8
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 297
- group Id
- BG001
- value
- 291
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 588
- title
- White
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 17
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 37
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 81
- group Id
- BG001
- value
- 84
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 171
- title
- Favorable
- measurements
- group Id
- BG000
- value
- 248
- group Id
- BG001
- value
- 242
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 493
- title
- Intermediate
- measurements
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 91
- title
- Poor
- description
- Stratification factor per case report form based on the following risk factors: baseline Karnofsky Performance Status \<80%; interval between initial diagnosis of renal cell carcinoma to start of first-line systemic treatment for advanced disease \<1year; baseline hemoglobin \<lower limit of normal (LLN); baseline platelet count \>upper limit of normal (ULN); baseline corrected serum calcium \>ULN; and baseline neutrophil \>ULN. The category was determined by totaling the risk factors per participant: favorable (0 factors); intermediate (1-2 factors); and poor (≥3 factors).
- param Type
- COUNT_OF_PARTICIPANTS
- title
- International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Risk Category
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 186
- group Id
- BG001
- value
- 190
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 379
- title
- 1
- measurements
- group Id
- BG000
- value
- 188
- group Id
- BG001
- value
- 182
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 376
- title
- 2-3
- description
- Stratification factor per case report form, the number of prior VEGF/VEGF-Receptor targeted therapies that they received to treat their advanced Renal Cell Carcinoma (RCC): 1 versus 2-3.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Number of Prior Vascular Endothelial Growth Factor (VEGF)/VEGF-Receptor Targeted Therapies
- unit Of Measure
- Participants
- population Description
- Per protocol, the 9 participants enrolled in the Safety Run-In were not randomized and not included in the protocol-specified analyses for any of the outcome measures.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 374
- group Id
- BG001
- value
- 372
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 755
- units
- Participants
- groups
- description
- Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.
- id
- BG000
- title
- Belzutifan
- description
- Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.
- id
- BG001
- title
- Everolimus
- description
- Non-Randomized participants enrolled into the Safety Run-in received up to 120 mg of belzutifan QD.
- id
- BG002
- title
- Safety Run-In
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.2
- value
- 61.6
- group Id
- BG001
- spread
- 9.7
- value
- 63.1
- group Id
- BG002
- spread
- 6.6
- value
- 70.0
- group Id
- BG003
- spread
- 10.0
- value
- 62.4
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 77
- group Id
- BG001
- value
- 88
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 169
- title
- Female
- measurements
- group Id
- BG000
- value
- 297
- group Id
- BG001
- value
- 284
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 586
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 37
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 78
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 300
- group Id
- BG001
- value
- 303
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 612
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 33
- group Id
- BG001
- value
- 32
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 65
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 5
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 47
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 99
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 8
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 297
- group Id
- BG001
- value
- 291
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 588
- title
- White
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 17
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 37
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 81
- group Id
- BG001
- value
- 84
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 171
- title
- Favorable
- measurements
- group Id
- BG000
- value
- 248
- group Id
- BG001
- value
- 242
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 493
- title
- Intermediate
- measurements
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 91
- title
- Poor
- description
- Stratification factor per case report form based on the following risk factors: baseline Karnofsky Performance Status \<80%; interval between initial diagnosis of renal cell carcinoma to start of first-line systemic treatment for advanced disease \<1year; baseline hemoglobin \<lower limit of normal (LLN); baseline platelet count \>upper limit of normal (ULN); baseline corrected serum calcium \>ULN; and baseline neutrophil \>ULN. The category was determined by totaling the risk factors per participant: favorable (0 factors); intermediate (1-2 factors); and poor (≥3 factors).
- param Type
- COUNT_OF_PARTICIPANTS
- title
- International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Risk Category
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 186
- group Id
- BG001
- value
- 190
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 379
- title
- 1
- measurements
- group Id
- BG000
- value
- 188
- group Id
- BG001
- value
- 182
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 376
- title
- 2-3
- description
- Stratification factor per case report form, the number of prior VEGF/VEGF-Receptor targeted therapies that they received to treat their advanced Renal Cell Carcinoma (RCC): 1 versus 2-3.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Number of Prior Vascular Endothelial Growth Factor (VEGF)/VEGF-Receptor Targeted Therapies
- unit Of Measure
- Participants
- population Description
- Per protocol, the 9 participants enrolled in the Safety Run-In were not randomized and not included in the protocol-specified analyses for any of the outcome measures.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle